Governor Mike DeWine and the Ohio Department of Health have advised all Ohio vaccine providers to temporarily pause distribution of the Johnson & Johnson in accordance with a joint statement released by the Food and Drug Administration and the Centers for Disease Control and Prevention. This recommendation to suspend distribution was issued out of an abundance of caution after several cases of rare and serious blood clots emerged in 6 women between the ages of 18 and 48. Symptom onset for these individuals occurred 6-13 days after receiving the Johnson & Johnson vaccine.
If you received a Johnson & Johnson vaccination before March 22nd, the risk of developing cerebral venous sinus thrombosis (CVST) or thromobocytopenia from the vaccine is very low.
People who received the Johnson & Johnson vaccine after March 22nd should monitor for symptoms including severe headache, abdominal pain, leg pain, and/or shortness of breath. If you develop any of these symptoms please contact your medical provider for further guidance and to let them know you were given with the Johnson & Johnson vaccine.
At-risk symptoms may develop between 1 to 3 weeks after vaccination with an average of 9 days.
It is common for individuals to experience flu-like symptoms within the first few days of vaccination, including mild headache, fatigue, joint-achiness, and fever. These symptoms are common for all three vaccines. If you have questions about persistent symptoms, contact your medical provider.
TLCHD will continue all scheduled vaccination clinics at this time. Moderna or Pfizer vaccine will be made available for previously scheduled Johnson & Johnson clinics, until further notice.